"Blinding" of AMP-dependent kinase by methylglyoxal: A mechanism that allows perpetuation of hepatic insulin resistance?

Medical Hypotheses

Volumn 73, Issue 6, 2009, Pages 921-924

  Gugliucci, A ^a  

^a TOURO UNIVERSITY CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE MONOPHOSPHATE DEPENDENT PROTEIN KINASE; ADENOSINE PHOSPHATE; ARGININE; GLITAZONE DERIVATIVE; GLUCOSE; METFORMIN; METHYLGLYOXAL; PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; DIABETES MELLITUS; DRUG MECHANISM; ENERGY BALANCE; ENZYME ACTIVITY; ENZYME REGULATION; FATTY LIVER; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLYCATION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPOGENESIS; LIVER METABOLISM; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADENOSINE MONOPHOSPHATE; INSULIN RESISTANCE; LIVER; PROTEIN BINDING; PROTEIN KINASES; PYRUVALDEHYDE;

EID: 70450273227     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.06.044     Document Type: Article

References (36)

1. Petersen K.F., Dufour S., Befroy D., Lehrke M., Hendler R.E., and Shulman G.I. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54 (2005) 603-608
2. Hanley A.J., Festa A., D'Agostino Jr. R.B., Wagenknecht L.E., Savage P.J., Tracy R.P., et al. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes 53 (2004) 1773-1781
3. Hardie D.G. Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease. FEBS Lett. 582 (2008) 81-89
4. Forcet C., and Billaud M. Dialogue between LKB1 and AMPK: a hot topic at the cellular pole. Sci STKE 2007 (2007) 51
5. Hardie D.G. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8 (2007) 774-785
6. Hue L., and Rider M.H. The AMP-activated protein kinase: more than an energy sensor. Essays Biochem 43 (2007) 121-137
7. Towler M.C., and Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100 (2007) 328-341
8. Viollet B., Mounier R., Leclerc J., Yazigi A., Foretz M., and Andreelli F. Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes Metab 33 (2007) 395-402
9. Schimmack G., Defronzo R.A., and Musi N. AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes Obes Metab 8 (2006) 591-602
10. Hardie D.G. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 47 (2007) 185-210
11. Fujii N., Jessen N., and Goodyear L.J. AMP-activated protein kinase and the regulation of glucose transport. Am J Physiol Endocrinol Metab 291 (2006) E867-E877
12. Reznick R.M., and Shulman G.I. The role of AMP-activated protein kinase in mitochondrial biogenesis. J Physiol 574 (2006) 33-39
13. Jorgensen S.B., Richter E.A., and Wojtaszewski J.F. Role of AMPK in skeletal muscle metabolic regulation and adaptation in relation to exercise. J Physiol 574 (2006) 17-31
14. Nakamaru K., Matsumoto K., Taguchi T., Suefuji M., Murata Y., Igata M., et al. AICAR, an activator of AMP-activated protein kinase, down-regulates the insulin receptor expression in HepG2 cells. Biochem Biophys Res Commun 328 (2005) 449-454
15. Leverve XM, Guigas B, Detaille D, Batandier C, Koceir EA, Chauvin C, et al. Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 2003; 29:6S88-94.
16. Winder W.W. AMP-activated protein kinase: possible target for treatment of type 2 diabetes. Diabetes Technol Ther 2 (2000) 441-448
17. Musi N. AMP-activated protein kinase and type 2 diabetes. Curr Med Chem 13 (2006) 583-589
18. Hou X., Xu S., Maitland-Toolan K.A., Sato K., Jiang B., Ido Y., et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem (2008)
19. Zang M., Xu S., Maitland-Toolan K.A., Zuccollo A., Hou X., Jiang B., et al. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55 (2006) 2180-2191
20. Beisswenger P., and Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab 29 (2003) 6S95-103
21. Townley R., and Shapiro L. Crystal structures of the adenylate sensor from fission yeast AMP-activated protein kinase. Science 315 (2007) 1726-1729
22. Vlassara H., and Palace M.R. Diabetes and advanced glycation endproducts. J Int Med 251 (2002) 87-101
23. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 (2005) 1615-1625
24. Brown S.M., Smith D.M., Alt N., Thorpe S.R., and Baynes J.W. Tissue-specific variation in glycation of proteins in diabetes: evidence for a functional role of amadoriase enzymes. Ann NY Acad Sci 1043 (2005) 817-823
25. Monnier V.M., Sell D.R., and Genuth S. Glycation products as markers and predictors of the progression of diabetic complications. Ann NY Acad Sci 1043 (2005) 567-581
26. Rabbani N., and Thornalley P.J. The dicarbonyl proteome: proteins susceptible to dicarbonyl glycation at functional sites in health, aging, and disease. Ann NY Acad Sci 1126 (2008) 124-127
27. Thornalley P.J. : Endogenous alpha-oxoaldehydes and formation of protein and nucleotide advanced glycation endproducts in tissue damage. Novartis Found Symp 285 (2007) 229-243 [discussion 243-226]
28. Ahmed N., Thornalley P.J., Dawczynski J., Franke S., Strobel J., Stein G., et al. Methylglyoxal-derived hydroimidazolone advanced glycation end-products of human lens proteins. Invest Ophthalmol Vis Sci 44 (2003) 5287-5292
29. Thornalley P.J., Langborg A., and Minhas H.S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344 Pt 1 (1999) 109-116
30. Reaven P. Metabolic syndrome. J Insur Med 36 (2004) 132-142
31. Reaven G.M. The metabolic syndrome: is this diagnosis necessary?. Am J Clin Nutr 83 (2006) 1237-1247
32. Gugliucci A., and Menini T. The polyamines spermine and spermidine protect proteins from structural and functional damage by AGE precursors: a new role for old molecules?. Life Sci 72 (2003) 2603-2616
33. Gugliucci A. Alternative antiglycation mechanisms: are spermine and fructosamine-3-kinase part of a carbonyl damage control pathway?. Med Hypotheses 64 (2005) 770-777
34. Michell B.J., Stapleton D., Mitchelhill K.I., House C.M., Katsis F., Witters L.A., et al. Isoform-specific purification and substrate specificity of the 5′-AMP-activated protein kinase. J Biol Chem 271 (1996) 28445-28450
35. Trumble G.E., Smith M.A., and Winder W.W. Purification and characterization of rat skeletal muscle acetyl-CoA carboxylase. Eur J Biochem 231 (1995) 192-198
36. Zang M., Zuccollo A., Hou X., Nagata D., Walsh K., Herscovitz H., et al. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 279 (2004) 47898-47905